Ipsen

News

Gilead, Ipsen build the case for their PBC drugs at EASL

Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointin

News

Ipsen signs $1.8bn RNA drug alliance with Skyhawk

Ipsen has expanded its R&D pipeline once again, agreeing a $1.8 billion alliance with Skyhawk Therapeutics focused on the development of RNA-targeting therapies for ra

News

Ipsen licenses Sutro ADC in $900m deal

Ipsen has expanded its oncology pipeline by licensing rights to an antibody-drug conjugate (ADC) for solid tumours from Sutro Biopharma, its first drug in the category.

News

UK access disparity resolved as NICE backs RCC therapy

Thousands of UK patients with advanced kidney cancer who have been denied a combination regimen based on Ipsen’s Cabometyx and Bristol-Myers Squibb’s Opdivo will now be ab

News

Onivyde gets ‘practice-changing’ FDA OK in pancreatic cancer

Ipsen has won FDA approval for first-line use of its pancreatic cancer therapy Onivyde, saying it is now part of a potential new “standard-of-care” for patients.

News

Ipsen/Genfit eye June FDA verdict for liver drug elafibranor

The FDA has kicked off a priority review of Genfit and Ipsen’s elafibranor as a treatment for rare cholestatic liver disease primary biliary cholangitis (PBC), setting a d

Gilead, Ipsen build the case for their PBC drugs at EASL

Ipsen signs $1.8bn RNA drug alliance with Skyhawk

Ipsen licenses Sutro ADC in $900m deal

UK access disparity resolved as NICE backs RCC therapy

Onivyde gets ‘practice-changing’ FDA OK in pancreatic cancer

Ipsen/Genfit eye June FDA verdict for liver drug elafibranor

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Ipsen

Editor's Picks